<DOC>
	<DOCNO>NCT00729183</DOCNO>
	<brief_summary>This study evaluate safety treatment effect 50 mg MK0822 Vitamin D v placebo Vitamin D postmenopausal woman low bone density .</brief_summary>
	<brief_title>BMD Efficacy Safety Odanacatib Postmenopausal Women ( 0822-031 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>Postmenopausal 3 year , tscore &lt; =1.5 &gt; 3.5 , hip contain hardware orthopedic procedure , ambulatory Patient previous hip fracture Patient &gt; 1 prior clinical vertebral fracture AND candidate osteoporosis therapy Patient treat oral bisphosphonates , strontium , PTH agent effect bone Patient metabolic bone disorder osteoporosis Patient renal stone , Parkinson 's disease , MS active parathyroid disease .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>